Corporate Venture "Parents" Rarely Buy Or Partner With Biotech Investments
This article was originally published in Start Up
Executive Summary
Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.
You may also be interested in...
Nimbus Thinks It Has “Non-First-Mover” Advantage In NASH
Working on an allosteric ACC inhibitor in NASH, Nimbus is not worried about being first to market but is willing to let others develop and prove out a pivotal development pathway in the indication, while it focuses on a unique mechanism of action.
The A-List: The Trend-Shaping Series A Financings Of 2014
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
Corporate VC Backing Influences Private M&A Step-Ups
New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.